<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6265273</article-id><article-id pub-id-type="pmid">30420612</article-id><article-id pub-id-type="publisher-id">289</article-id><article-id pub-id-type="doi">10.1038/s41416-018-0289-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kim</surname><given-names>Bo-Kyung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Nam</surname><given-names>Soon Woo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Min</surname><given-names>Byung Soh</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ban</surname><given-names>Hyun Seung</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Paik</surname><given-names>Soonmyung</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kyeong</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Im</surname><given-names>Joo-Young</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Youngjoo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Joon-Tae</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Seon-Young</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Mirang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Hongsub</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Won</surname><given-names>Misun</given-names></name><address><phone>+82-42-860-4178</phone><email>misun@kribb.re.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0636 3099</institution-id><institution-id institution-id-type="GRID">grid.249967.7</institution-id><institution>Personalized Genomic Medicine Research Center, KRIBB, </institution></institution-wrap>Daejeon, 34141 Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0371 5685</institution-id><institution-id institution-id-type="GRID">grid.464585.e</institution-id><institution>The Catholic University of Korea, Incheon St Mary&#x02019;s Hospital, </institution></institution-wrap>56 Dongsuro Bupyunggu, Incheon, 06591 Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5454</institution-id><institution-id institution-id-type="GRID">grid.15444.30</institution-id><institution>Serverance Biomedical Science Institute, </institution><institution>Yonsei University College of Medicine, </institution></institution-wrap>Seoul, 03722 Korea </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0636 3099</institution-id><institution-id institution-id-type="GRID">grid.249967.7</institution-id><institution>Metabolic Regulation Research Center, KRIBB, </institution></institution-wrap>Daejeon, 34141 Korea </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0671 5021</institution-id><institution-id institution-id-type="GRID">grid.255168.d</institution-id><institution>College of Pharmacy, </institution><institution>Dongguk University-Seoul, </institution></institution-wrap>Goyang, 410-820 Korea </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0648 021X</institution-id><institution-id institution-id-type="GRID">grid.497705.8</institution-id><institution>Drug Discovery Team, ILDONG Pharmaceutical Co. Ltd., Hwaseong, </institution></institution-wrap>Hwaseong, 445-811 Korea </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1791 8264</institution-id><institution-id institution-id-type="GRID">grid.412786.e</institution-id><institution>Department of Functional Genomics, KRIBB School of Bioscience, </institution><institution>Korea University of Science and Technology (UST), 217 Gajeong-ro, Yuseong-gu, Daejeon, Korea, </institution></institution-wrap>Daejeon, 34113 Korea </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="ppub"><day>27</day><month>11</month><year>2018</year></pub-date><volume>119</volume><issue>11</issue><fpage>1347</fpage><lpage>1357</lpage><history><date date-type="received"><day>3</day><month>4</month><year>2018</year></date><date date-type="rev-recd"><day>22</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>13</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; Cancer Research UK 2018</copyright-statement><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The IDF-11774, a novel clinical candidate for cancer therapy, targets HSP70 and inhibits mitochondrial respiration, resulting in the activation of AMPK and reduction in HIF-1&#x003b1; accumulation.</p></sec><sec><title>Methods</title><p id="Par2">To identify genes that have synthetic lethality to IDF-11774, RNA interference screening was conducted, using pooled lentiviruses expressing a short hairpin RNA library.</p></sec><sec><title>Results</title><p id="Par3">We identified <italic>ATP6V0C</italic>, encoding the V0 subunit C of lysosomal V-ATPase, knockdown of which induced a synergistic growth-inhibitory effect in HCT116 cells in the presence of IDF-11774. The synthetic lethality of IDF-11774 with <italic>ATP6V0C</italic> possibly correlates with IDF-11774-mediated autolysosome formation. Notably, the synergistic effect of IDF-11774 and the ATP6V0C inhibitor, bafilomycin A1, depended on the PIK3CA genetic status and Bcl-2 expression, which regulates autolysosome formation and apoptosis. Similarly, in an experiment using conditionally reprogramed cells derived from colorectal cancer patients, synergistic growth inhibition was observed in cells with low Bcl-2 expression.</p></sec><sec><title>Conclusions</title><p id="Par4">Bcl-2 is a biomarker for the synthetic lethal interaction of IDF-11774 with <italic>ATP6V0C</italic>, which is clinically applicable for the treatment of cancer patients with IDF-11774 or autophagy-inducing anti-cancer drugs.</p></sec></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Macroautophagy</kwd><kwd>Gene regulation</kwd><kwd>Drug development</kwd><kwd>Colon cancer</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea (NRF)</institution></institution-wrap></funding-source><award-id>2012M3A9C1053532</award-id><award-id>2018R1A5A2023127</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Kyeong</given-names></name><name><surname>Won</surname><given-names>Misun</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Health Technology R&#x00026;D : HI13C2162</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Cancer Research UK 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par5">Synthetic lethality is traditionally defined as a type of genetic interaction in which the simultaneous mutation of two genes leads to cell death, while mutation of only one of them does not.<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup> Recently, the concept of synthetic lethality has been extended to include chemical&#x02013;genetic and chemical&#x02013;chemical interactions.<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup> Information on synthetic lethality contributes to the understanding of gene functions, mechanisms of drug action, and genetic relations, and to the development of therapeutic strategies for patients with cancer. Genome-wide RNA interference (RNAi) screening has been widely applied to identify various synthetic lethal interactions on the basis of mutated genes or anti-cancer drugs in cancer cells.<sup><xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref></sup> In a screening of a kinome short hairpin RNA (shRNA) library, vemurafenib, a drug used in sensitive <italic>BRAF</italic>-mutant colon cancers, showed synergy with knockdown of the epidermal growth factor receptor gene (<italic>EGFR</italic>), indicating a synthetic lethal interaction of <italic>B-RAF</italic> and <italic>EGFR</italic>.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> The gene encoding neurofibromin, a negative regulator of RAS signaling, confers resistance to tamoxifen based on a genome-wide RNAi screen.<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> Moreover, a KEAP1-dependent synthetic lethal interaction of <italic>TXNRD1</italic> with AKT inhibitors in cancer has been demonstrated.<sup><xref ref-type="bibr" rid="CR10">10</xref></sup></p><p id="Par6">Colorectal cancer is one of the most common causes of cancer-related mortality worldwide.<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup> According to a report of The Cancer Genome Atlas Project (TCGA) on human colorectal carcinoma, the most frequently mutated genes are <italic>APC</italic>, <italic>TP53</italic>, <italic>KRAS</italic>, <italic>PIK3CA</italic>, <italic>FBXW7</italic>, <italic>SMAD4</italic>, <italic>TCF7L2</italic>, and <italic>NRAS</italic> in non-hypermutated tumors; and <italic>BRAF</italic>, <italic>ACVR2A</italic>, <italic>APC</italic>, <italic>TGFBR2</italic>, <italic>MSH3</italic>, <italic>MSH6</italic>, <italic>SLC9A9</italic>, and <italic>TCF7L2</italic> in hypermutated tumors.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> Genetic alterations in the phosphatidylinositide-3-kinase (PI3K) and RAS&#x02013;MAPK pathways are common, and co-occurrence of alterations in both pathways is observed in approximately one-third of colorectal cancers. In addition, coexistent mutations in exons 9 and 20 of <italic>PIK3CA</italic>, which encodes the p110&#x003b1; catalytic subunit of PI3K, are associated with poor prognosis.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> However, the prognostic significance of <italic>PIK3CA</italic> mutations in colorectal cancer remains unclear.</p><p id="Par7">The multikinase inhibitor regorafenib as well as the antibodies bevacizumab and cetuximab, have been approved by the FDA for the targeted therapy of colorectal cancer. However, cytotoxic chemotherapy using 5-fluorouracil (5-FU), oxaliplatin, and irinotecan is used frequently to slow down the growth of incurable metastatic colorectal cancers.<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup> Recently, we reported that IDF-11774, a novel clinical candidate, stimulates hypoxia-inducible factor alpha (HIF-1&#x003b1;) degradation, presumably by inhibiting HSP70 chaperone activity.<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup> IDF-11774 regulates cancer metabolism by activating AMP-activated protein kinase (AMPK).<sup><xref ref-type="bibr" rid="CR17">17</xref></sup></p><p id="Par8">To identify genes that are synthetic lethal to IDF-11774, we carried out RNAi screening using pooled lentiviruses expressing an shRNA library and then isolated the genes whose knockdown induced a synergistic growth-inhibitory effect in cancer cells in the presence of IDF-11774. We revealed that <italic>ATP6V0C</italic>, encoding the V0 subunit C of lysosomal V-ATPase, is synthetic lethal with IDF-11774, and this effect correlates with <italic>PIK3CA</italic> mutation and low B-Cell CLL/Lymphoma 2 (Bcl-2) expression. In this study, we provided a rationale for combined treatment with IDF-11774 and an ATP6V0C inhibitor for patients with colorectal cancer that harbor <italic>PIK3CA</italic> mutations and thus, exhibit low Bcl-2 expression.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Chemicals, antibodies, and reagents</title><p id="Par9">Bafilomycin A1 (BM), concanamycin A (CCM), chloroquine (CQ), 3-methyladenine (3-MA), 5-fluorouracil (5-FU), and 2-phenylethynesulfonamide (PES) were purchased from Sigma-Aldrich (St. Louis, MO, USA). siRNAs were obtained from Bioneer (Deajeon, Korea). The following antibodies were used: Bcl-2 (ab32124, Abcam, Cambrige, MA, USA), Bcl-xl (2764, Cell Signaling Technology), Bak1 (3814, Cell Signaling Technology), ATP6V0C (ab104374, Abcam), LC3B (2775, Cell Signaling Technology, Beverly, MA, USA), PARP-1 (9542, Cell Signaling Technology), PIK3CA (4249, Cell Signaling Technology), HA (2367, Cell Signaling Technology), Myc (sc-789, Santa Cruz Biotechnology) and GAPDH (LF-PA0212, AbFrontier Co., Ltd, Seoul, Korea).</p></sec><sec id="Sec4"><title>Cell culture and IncuCyte system</title><p id="Par10">The HT29, WiDr, colo320, colo205, SW620, SW480, HCT15, DLD-1, HCC2998, and LoVo human colorectal adenocarcinoma cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS). The HCT116 human colorectal adenocarcinoma cells and CCD-18Co human colon fibroblast cells were cultured in DMEM medium containing 10% (v/v) FBS. All cells were cultured at 37&#x02009;&#x000b0;C with 5% CO<sub>2</sub>.</p><p id="Par11">To analyze cell proliferation, the proliferation rates based on cell confluency were determined by live cell imaging (IncuCyte ZOOM system, Essen Bioscience, Ann Arbor, MI, USA). To analyze apoptosis, kinetic caspase-3/7 measurements were assayed using the CellPlayer reagent (Essen Bioscience) as described previously.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> The frames of the cells incubating in 96-well plates were captured at 2&#x02009;h intervals from four separate regions per well using a &#x000d7;10 objective lens. Cultures were maintained in a 37&#x02009;&#x000b0;C incubator.</p></sec><sec id="Sec5"><title>Establishment and culture of conditionally reprogrammed colorectal cancer cells</title><p id="Par12">Conditionally reprogrammed colorectal cancer cells were established at Yonsei University as previously described.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> In brief, a fresh colorectal cancer surgical specimen was washed with PBS and cut into 0.5&#x02009;mm-sized pieces and then incubated with 0.1% trypsin-EDTA with 5% penicillin-streptomycin at 37&#x02009;&#x000b0;C for 5&#x02009;min. The trypsin was neutralized by Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM). After centrifugation, the cell pellet was resuspended and incubated in DMEM with collagenase 1A and 5% penicillin-streptomycin at 37&#x02009;&#x000b0;C for ~1.5&#x02009;h. The suspended medium was filtered with a cell strainer (70&#x02009;&#x003bc;m pore size) and then centrifuged. The pellet was resuspended in DMEM and plated on cell culture dishes in F-medium with ROCK inhibitor (Y-27632, STEMCELL Technologies Inc., Seoul, Korea). Irradiated 3T3-J2 cells (generously provided by Dr. Richard Schiegel at Georgetown University) were used as feeder cells. Cells were co-cultured with irradiated 3T3 fibroblasts in F-media (F-12/DMEM medium, 3:1&#x02009;v/v), 5% FBS, 0.4&#x02009;&#x003bc;g/ml hydrocortisone, 5&#x02009;&#x003bc;g/ml insulin, 8.4&#x02009;ng/ml cholera toxin, 10&#x02009;ng/ml epidermal growth factor, 24&#x02009;&#x003bc;g/ml adenine, and 5&#x02009;&#x000b5;M Y-27632 as described.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup></p></sec><sec id="Sec6"><title>RNAi screening using shRNA expressing lentivirus library</title><p id="Par13">The human module 1 lentiviral shRNA library containing 27,500 shRNAs targeting 5043 genes (Cellecta, Mountain View, CA, USA) was used for synthetic lethal screening according to the manufacturer&#x02019;s protocol. Briefly, the shRNA library was packaged into lentivirus via HEK293T cells using Lipofectamine and Plus Reagent (Invitrogen, Carlsbad, CA, USA), and then were transduced into HCT116 cells with multiplicity of infection of 0.7 and average 500 cells per shRNA construct. The transfection efficiency was estimated by measuring red fluorescent protein (RFP) by fluorescence activated cell sorting. Then, 48&#x02009;h post-transduction, HCT116 cells were selected with puromycin (1&#x02009;&#x003bc;g/ml) for 72&#x02009;h. An aliquot of the transduced HCT116 cells was preserved as a reference sample (C1). The remaining cells were divided into two samples: one treated with 5&#x02009;&#x003bc;M IDF-11774 for 96&#x02009;h and the other with dimethyl sulfoxide (C2). The shRNA insert barcodes were amplified from genomic DNA using a Pfu PCR premix (Bioneer, Daejeon, Korea), and then sequenced using Illumina Hi-Seq 2500 system (Illumina, Inc. San Diego, CA, USA).</p></sec><sec id="Sec7"><title>Gene knockdown using siRNA</title><p id="Par14">Gene knockdown was performed by introducing siRNA of the target gene via Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer&#x02019;s instructions. siRNA sequences are listed in Supplementary Table&#x000a0;<xref rid="MOESM9" ref-type="media">1</xref>.</p></sec><sec id="Sec8"><title>Western blot analysis</title><p id="Par15">Western blot was performed as described.<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> Cell lysates were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene fluoride (PVDF) membranes. Western blot bands were quantified using Image J software.</p></sec><sec id="Sec9"><title>Reverse-transcription polymerase chain reaction (RT-PCR)</title><p id="Par16">Total RNA was isolated using Trizol reagent (Invitrogen) and cDNA was synthesized using TOPscript&#x02122; RT DryMIX (Enzynomics, Seoul, Korea). The sequences of the primers that were used are provided in Supplementary Table&#x000a0;<xref rid="MOESM10" ref-type="media">2</xref>. PCR products were analyzed by agarose-gel electrophoresis and visualized by ethidium bromide staining.</p></sec><sec id="Sec10"><title>Sulforhodamine B (SRB) assay and Combination Index</title><p id="Par17">Growth inhibition of cells was assessed using SRB. The cells fixed with 10% formalin (Sigma-Aldrich) were stained with 0.4% sulforhodamine B. Protein-bound dye was dissolved in 10&#x02009;mM Tris, and its optical density was measured at 540&#x02009;nm. Combination Index (CI) values were calculated using the median effect analysis method.<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> The CI is a quantitative measure of the degree of interaction between two drugs. A synergistic effect is defined as CI&#x02009;&#x0003c;&#x02009;1, an additive effect as CI&#x02009;=&#x02009;1, and an antagonistic effect as CI&#x02009;&#x0003e;&#x02009;1.</p></sec><sec id="Sec11"><title>LysoTracker labeling</title><p id="Par18">To stain acidic autolysosomes,<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup> the cells were incubated with LysoTracker (Molecular Probes, Life Technologies, Carlsbad, CA, USA) for 30&#x02009;min at 37&#x02009;&#x000b0;C. The LysoTracker-labeled cells were observed with a confocal fluorescence microscope (LSM5 Live DuoScan; Carl Zeiss, Stuttgart, Germany) and analyzed using live cell imaging. The number of LysoTracker positive cells was normalized to the number of total cells.</p></sec><sec id="Sec12"><title>FITC-Annexin V/PI double staining</title><p id="Par19">An FITC-Annexin V/propidium iodine (PI) double-staining analysis was performed according to the manufacturer&#x02019;s protocol (BD Biosciences). The cells were treated with IDF-11774 and bafilomycin A1 and then washed twice with pre-chilled phosphate-buffered saline (PBS). The treated cells were stained with FITC-Annexin V staining buffer and PI solution for 15&#x02009;min at room temperature and then analyzed with a FACSCalibur Flow Cytometer (BD Biosciences).</p></sec><sec id="Sec13"><title>Immunofluorescence staining</title><p id="Par20">Immunofluorescence staining was performed as described previously.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> The cells were incubated with the LC3B antibody overnight at 4&#x02009;&#x000b0;C and incubated with conjugated secondary antibody for 1&#x02009;h at room temperature. The cells were washed with PBS and then stained with 4&#x02019;,6-diamidino-2-phenylindole for 5&#x02009;min, and then were observed with a confocal fluorescence microscope (LSM5 Live DuoScan; Carl Zeiss, Stuttgart, Germany). For mRFP-GFP-tagged LC3 assay, cells were transfected with ptfLC3 (Addgene, Cambridge, MA, USA), which contains a gene encoding mammalian expression of rat LC3 fused to mRFP and EGFP, and then observed using confocal fluorescence microscope. Autophgic flux was analyzed by monitoring the change of mRFP-GFP-LC3B fluorescence.</p></sec><sec id="Sec14"><title>Immunohistochemistry</title><p id="Par21">The tissue array block of human colorectal cancer and normal tissues were supplied by US Biomax (Rockville, MD, USA). The immunohistochemistry was performed as previously described.<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> The slides were incubated with the anti-ATP6V0C antibody, respectively, followed by incubation with biotinylated anti-rabbit IgG secondary antibody (Vector Laboratories, Burlingame, CA, USA) and avidin&#x02013;biotin peroxidase (Vector Laboratories) and visualized using diaminobenzidine tetrahydrochloride (Vector Laboratories). Nuclear counterstaining was accomplished with hematoxylin.</p></sec><sec id="Sec15"><title>Immunoprecipitation</title><p id="Par22">Immunoprecipitation assays were performed using Protein A/G agarose beads as recommended by the manufacturer (Santa Cruz Biotechnology, Santa Cruz, CA, USA). HCT116 cells transfected with pCMV3-HA-Bcl-2 and pCMV3-Myc-Bax were treated with 10&#x02009;&#x000b5;M IDF-11774 and 1&#x02009;nM bafilomycin A1. Cell extracts (300&#x02009;&#x000b5;g) were incubated with anti-HA-Agarose at 4&#x02009;&#x000b0;C overnight. Normal IgG was used as a control. The agarose beads were precipitated and washed. Proteins bound to the beads were detected by western blot analysis.</p></sec><sec id="Sec16"><title>In vivo xenograft assay</title><p id="Par23">The in vivo anti-tumor activity of IDF-11774 was analyzed using the human colon cancer HCT116 cells. Cells were injected subcutaneously into 6-week-old female Balb/c nude mice to generate tumors (5 mice per group). After 7 days, the transplanted mice was treated with IDF-11774 (20&#x02009;mg/kg/day) by oral administration (per os; p.o.) for 15 days. For combination treatment, the mice were injected intraperitoneally (i.p.) with bafilomycin A1 (0.5&#x02009;mg/kg) daily. Tumor volume (V) was determined using the following equation: V (mm<sup>3</sup>)&#x02009;=&#x02009;(Length&#x02009;&#x000d7;&#x02009;Width&#x02009;&#x000d7;&#x02009;Height)&#x02009;&#x000d7;&#x02009;0.5.</p></sec><sec id="Sec17"><title>Statistical analyses</title><p id="Par24">A Student&#x02019;s <italic>t-</italic>test or Chi-square test was used for statistical analyses. Bars indicate S.D. and asterisks denote significant differences (***<italic>p</italic>&#x02009;&#x02264;&#x02009;0.005, **<italic>p</italic>&#x02009;&#x02264;&#x02009;0.01, *<italic>p</italic>&#x02009;&#x02264;&#x02009;0.05) of means between the two groups.</p></sec></sec><sec id="Sec18" sec-type="results"><title>Results</title><sec id="Sec19"><title><italic>ATP6V0C</italic> is identified as a synthetic lethal partner of IDF-11774 by shRNA screening in HCT116 cells</title><p id="Par25">We performed chemogenetic RNAi screening using pooled lentiviruses expressing a shRNA library in HCT116 cells. Barcode read count analysis revealed 51 candidates whose knockdown induced significant cell death in combination with IDF-11774 treatment as compared with the initial culture (C1) and continued culture without IDF-11774 treatment (C2) as controls, respectively. We analyzed the 51 genes using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and identified cell cycle, proteolysis, and lysosome as major gene association networks (Supplementary Figure&#x000a0;<xref rid="MOESM1" ref-type="media">1A</xref>). The Kyoto Encyclopedia of Genes and Genomes pathway analysis identified proteasome, PI3K-Akt signaling, cell cycle, metabolic pathway, lysosome, and AMPK signaling pathways (Supplementary Figure&#x000a0;<xref rid="MOESM1" ref-type="media">1B</xref>). As potential genes for synthetic lethality with IDF-11774 in HCT116, we selected 10 genes <italic>ATP6V0C</italic>, <italic>LAMP1</italic>, <italic>BCL2L1</italic>, <italic>RAN</italic>, <italic>RBX1, CAMK4</italic>, <italic>MAPKAPK5, PSMA1</italic>, PSMA7, and <italic>PSMB7</italic> based on pathway analysis and investigated the effect of their knockdown on growth inhibition of cells in the presence of IDF-11774 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, Supplementary Figure&#x000a0;<xref rid="MOESM1" ref-type="media">1C</xref>). We observed that knockdown of <italic>ATP6V0C</italic> resulted in substantial growth inhibition in the presence of IDF-11774 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). We confirmed the dose-dependent chemosensitization of HCT116 cells to IDF-11774 by <italic>ATP6V0C</italic> knockdown (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). Live cell image analysis also indicated that <italic>ATP6V0C</italic> knockdown caused synergistic growth inhibition of HCT116 cells in the presence of IDF-11774 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). Because IDF-11774 targets HSP70,<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> we examined the effect of <italic>ATP6V0C</italic> knockdown in the presence of the HSP70 inhibitor 2-phenylethynesulfonamide (PES). As expected, <italic>ATP6V0C</italic> knockdown and simultaneous treatment with PES caused synergistic growth inhibition of HCT116 cells (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>). We next confirmed that bafilomycin A1, an ATP6V0C inhibitor, substantially inhibited the growth of cancer cells in combined treatment with IDF-11774 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1e</xref>). Moreover, combined treatment with bafilomycin A1 and PES also synergistically inhibited HCT116 cell growth (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1f</xref>). However, bafilomycin A1 did not sensitize HCT116 cells to 5-FU, another chemotherapy drug (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1g</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>RNA interference (RNAi) screening to identify candidate genes sensitizing HCT116 cells to IDF-11774. <bold>a</bold> Knockdown effect of candidate genes on cell growth of HCT116 cells treated with 10&#x02009;&#x000b5;M IDF-11774. <bold>b</bold> Effect of <italic>ATP6V0C</italic> knockdown on the growth of HCT116 cells treated with different concentrations of IDF-11774 for 72&#x02009;h. Cell viability was analyzed by the sulforhodamine B (SRB) assay. Results are shown as the mean&#x02009;&#x000b1;&#x02009;S.D. of the three independent experiments. <bold>c</bold>, <bold>d</bold> Effect of <italic>ATP6V0C</italic> knockdown on the growth of HCT116 cells treated with 5&#x02009;&#x003bc;M IDF-11774 or 5&#x02009;&#x003bc;M 2-phenylethynesulfonamide (PES). <bold>e</bold>&#x02013;<bold>g</bold> Effect of bafilomycin A1 (BM, 1&#x02009;nM) on the growth of HCT116 cells treated with 5&#x02009;&#x003bc;M IDF-11774, 5&#x02009;&#x003bc;M PES or 5&#x02009;&#x003bc;M fluorouracil (5-FU). Cell growth was evaluated by live-cell imaging (IncuCyte ZOOM system). Data are presented as the single representative result of three experiments as the mean&#x02009;&#x000b1;&#x02009;S.D. In each experiment, each treatment was repeated in triplet wells, and each well was analyzed in 4 frames</p></caption><graphic xlink:href="41416_2018_289_Fig1_HTML" id="d29e835"/></fig></p></sec><sec id="Sec20"><title><italic>ATP6V0C</italic> knockdown blocks IDF-11774-induced autophagy</title><p id="Par26">IDF-11774 activates AMPK and inhibits the mTOR pathway,<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> indicating it induces autophagy. We observed that HCT116 cells treated with IDF-11774 accumulated microtubule-associated protein 1 light chain 3 beta (LC3B)-II, indicating autophagosome formation (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). ATP6V0C located in the lysosomal membrane transports protons to acidify lysosomes for autolysosome formation via autophagosome&#x02013;lysosome fusion.<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup> We examined the effects of 3-methyladenine (3-MA), a PI3K type III inhibitor that blocks autophagosome formation, and bafilomycin A1, which blocks autophagosome&#x02013;lysosome fusion, on autophagic flux in the presence of IDF-11774.<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup> We found that 3-MA suppressed the LC3B I&#x02013;II conversion and thus reduced LC3B-II accumulation in the presence of IDF-11774 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). By contrast, bafilomycin A1 enhanced LC3B-II accumulation in HCT116 cells treated with IDF-11774. Immunofluorescence staining confirmed that IDF-11774-induced LC3B-II accumulation was suppressed by pre-treatment with 3-MA, but not by bafilomycin A1 treatment (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). We next examined autolysosome formation using a double-tagged mRFP and GFP-LC3B reporter construct (ptfLC3) to discriminate autophagosomes and autolysosomes;<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup> autophagosomes, which were labeled with both mRFP and GFP, emitted yellow fluorescence, whereas autolysosomes emitted red fluorescence because of the degradation of GFP-LC3 in the acidic lysosomal condition. Red fluorescent vesicles increased in cells treated with IDF-11774, indicating the formation of functional autolysosomes by fusion of autophagosomes and lysosomes (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c, d</xref>). However, red fluorescent vesicles were hardly observed in cells treated with bafilomycine A1 in the presence of IDF-11774, indicating that functional autolysosomes were not formed. Next, we assessed whether functional autolysosome formation can be visualized using LysoTracker, which stains functional, acidified autolysosome.<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup> We observed the green fluorescence of LysoTracker mainly around functional lysosomes formed in the presence of IDF-11774 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>). As expected, the green fluorescence of functional lysosomes induced by IDF-11774 was reduced by pre-treatment with 3-MA or bafilomycin A1, indicating that the autophagy inhibitors disrupted IDF-11774-mediated autolysosome formation.<fig id="Fig2"><label>Fig. 2</label><caption><p>Synthetic lethal interaction of IDF-11774 with <italic>ATP6V0C</italic> in HCT116 cells. <bold>a</bold>, <bold>b</bold> Effect of autophagy inhibitor on LC3B accumulation in cells treated with IDF-11774 as analyzed by western blot analysis (<bold>a</bold>) and immunofluorescence (<bold>b</bold>). HCT116 cells were pre-incubated with 5&#x02009;mM 3-methyladenine (3-MA) or 1&#x02009;nM bafilomycin A1 (BM) for 3&#x02009;h and then treated with IDF-11774 for 18&#x02009;h. Scale bar, 10&#x02009;&#x000b5;m. Western blot band intensities were quantified using ImageJ. The signal intensity of LC3B was normalized to that of GAPDH. <bold>c</bold>, <bold>d</bold> Autolysosome formation of cells treated with IDF-11774 and 1&#x02009;nM bafilomycin A1 (BM). Representative images of confocal fluorescence microscopy (<bold>c</bold>) and quantification of positive cells for mRFP (red) and mRFP-GFP (yellow) in HCT116 cells transfected with ptfLC3 (<bold>d</bold>). Positive cells were counted using fluorescence microscopy (n&#x02009;=&#x02009;~70). Scale bar, 5&#x02009;&#x000b5;m. <bold>e</bold> Effect of autophagy inhibitor on autolysosome formation in cells treated with 5&#x02009;&#x003bc;M IDF-11774 and/or 1&#x02009;nM bafilomycine A1 for 18&#x02009;h. Autolysosome formation was assessed by LysoTracker staining. Arrows indicate autolysosomes. Scale bar, 10&#x02009;&#x000b5;m. <bold>f</bold> Effect of <italic>ATP6V0C</italic> knockdown using siATP6V0C on LC3B accumulation in cells treated with 5&#x02009;&#x003bc;M IDF-11774, as analyzed by western blotting. <bold>g</bold>, <bold>h</bold> Effect of <italic>ATP6V0C</italic> knockdown on autolysosome formation, as analyzed by LysoTracker staining (<bold>g</bold>) and the ratio of LysoTracker-positive to total HCT116 cells (<bold>h</bold>). Scale bar, 10&#x02009;&#x000b5;m</p></caption><graphic xlink:href="41416_2018_289_Fig2_HTML" id="d29e952"/></fig></p><p id="Par27">We then determined the effect of <italic>ATP6V0C</italic> knockdown on autophagy in HCT116 cells. <italic>ATP6V0C</italic> knockdown enhanced the LC3B-II accumulation induced by IDF-11774, as shown by western blotting (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2f</xref>), indicating autophagosome accumulation. We used LysoTracker to examine whether the combination of IDF-11774 treatment and <italic>ATP6V0C</italic> knockdown would affect functional autolysosome formation. <italic>ATP6V0C</italic> knockdown decreased IDF-11774-induced green fluorescence, indicating suppression of functional autolysosome formation (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2g, h</xref>). Thus, the inhibition of ATP6V0C blocked IDF-11774-induced functional autolysosome formation, resulting in autophagosome accumulation in HCT116 cells.</p></sec><sec id="Sec21"><title>Synergistic effect of IDF-11774 and <italic>ATP6V0C</italic> knockdown correlates with IDF-11774-mediated autolysosome formation</title><p id="Par28">To understand the clinical significance of ATP6V0C expression in colorectal cancer, we used a colorectal cancer tissue array for immunohistochemical analysis (Supplementary Figure&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>). ATP6V0C was highly expressed in 48% of colorectal cancer tissues (<italic>p</italic>&#x02009;<italic>=</italic>&#x02009;0.0006) and was significantly associated with lymph node metastasis (<italic>p</italic>&#x02009;<italic>=</italic>&#x02009;0.0002) (Supplementary Figure&#x000a0;<xref rid="MOESM2" ref-type="media">2B</xref>), suggesting its role in colorectal cancer progression. ATP6V0C expression was variable and high in HT29 and WiDr cells, but low in colo320 cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). We first examined whether the ATP6V0C expression level correlated directly with sensitivity to IDF-11774 in various colorectal cancer cell lines. <italic>ATP6V0C</italic> knockdown showed a synergistic effect on growth inhibition by IDF-11774 in WiDr, HT29, and HCT116 cells, but not in LoVo, colo320, and SW620 cells, suggesting that the ATP6V0C expression level was not relevant to IDF-11774 sensitivity (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>, Supplementary Table&#x000a0;<xref rid="MOESM11" ref-type="media">3</xref>). Therefore, we next examined the effect of IDF-11774 on autolysosome formation using LysoTracker. Strong green fluorescence was observed in HT29, WiDr, and HCT116 cells, but not in SW620, colo320, and Lovo cells, upon treatment with IDF-11774 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>). This result suggested that the synergistic cancer cell growth-inhibitory effect of IDF-11774 and <italic>ATP6V0C</italic> knockdown correlates with the ability for autolysosome formation in the presence of IDF-11774.<fig id="Fig3"><label>Fig. 3</label><caption><p>Synergistic effect of <italic>ATP6V0C</italic> and IDF-11774 on the growth of various colorectal cancer cells. <bold>a</bold> Western blot analysis of ATP6V0C levels in human colorectal cancer cells. The signal intensity of ATP6V0C was normalized to that of GAPDH. <bold>b</bold> Effect of <italic>ATP6V0C</italic> knockdown on the sensitivity of human colorectal cancer cells to IDF-11774. Cell viability was analyzed using the sulforhodamine B (SRB) assay. Results are shown as the mean&#x02009;&#x000b1;&#x02009;S.D. of three independent experiments. <bold>c</bold> LysoTracker staining for autolysosomes in various colorectal cancer cells. LysoTracker-positive cells as observed by fluorescence microscopy. Ratios of LysoTracker-positive to total cells are shown in the graph. Scale bar, 100&#x02009;&#x000b5;m. <bold>d</bold> Correlation of mutation status or expression of genes and combination index of two compounds. BM (bafilomycin A1), CCM (concanamycin A), and CQ (chloroquine) were used</p></caption><graphic xlink:href="41416_2018_289_Fig3_HTML" id="d29e1047"/></fig></p></sec><sec id="Sec22"><title><italic>PIK3CA</italic> genetic status is associated with the synthetic lethal interaction of IDF-11774 and functional autolysosome formation</title><p id="Par29">The IDF-11774-bafilomycin A1 combined treatment induced different responses in various colorectal cancer cell lines; therefore, we conducted isobologram analysis to characterize the relationship between IDF-11774 and the ATP6V0C inhibitors, bafilomycin A1 and concanamycin A, or the autophagosome&#x02013;lysosome fusion inhibitor, chloroquine, to identify genetic marker(s) in the cell lines (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3d</xref>). The ATP6V0C inhibitors demonstrated a synergistic effect (combination index [CI]&#x02009;&#x0003c;&#x02009;1) with IDF-11774 in HCT116, WiDr, and HT29 cells. However, in LoVo, colo320, and SW620 cells, all three inhibitors showed an antagonistic effect (CI&#x02009;&#x0003e;&#x02009;1) with IDF-11774, suggesting a crucial role for functional autolysosome formation in the synergistic effect. Therefore, we investigated the relevance of genetic mutations to the CI of IDF-11774 and functional autolysosome inhibition in the cancer cell lines. We found that <italic>PIK3CA</italic> mutation rendered colorectal cells significantly sensitive to the combined treatment with IDF-11774 and inhibitors of autophagosome&#x02013;lysosome fusion (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3d</xref>). This result suggested that the <italic>PIK3CA</italic> genetic status is probably associated with the synthetic lethality of IDF-11774 and the autophagy inhibitors.</p></sec><sec id="Sec23"><title>Combined treatment of IDF-11774 with bafilomycin A1 induces apoptosis in cancer cells</title><p id="Par30">To clarify the cell death induced by combined treatment with IDF-11774 and bafilomycin A1, we performed flow-cytometric analysis. We found that the G1 cell population of HCT116 and WiDr cells increased in the presence of IDF-11774. However, simultaneous treatment with IDF-11774 and bafilomycin A1 dramatically increased the sub-G1 population of HCT116 and WiDr cells, indicating the occurrence of apoptosis (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). Western blot analysis of cells treated with both IDF-11774 and bafilomycin A1 revealed the accumulation of LC3B-II and cleaved PARP-1, indicating the occurrence of apoptosis (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>). Moreover, Annexin V-propidium iodide double staining demonstrated that the combined treatment increased the pro-apoptotic and late-apoptotic populations in both cell lines (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c</xref>). In addition, caspase-3/7 assays using CellPlayer showed that combined treatment with IDF-11774 and bafilomycin A1 caused a substantial increase in caspase-3/7 activity compared with treatment with IDF-11774 alone in both WiDr (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4d</xref>) and HCT116 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4e</xref>) cells. These results suggested that IDF-11774 and bafilomycin A1 synergistically inhibited the growth of both WiDr and HCT116 cells by inducing apoptosis through blocking autolysosome formation.<fig id="Fig4"><label>Fig. 4</label><caption><p>Combined treatment of bafilomycin A1 and IDF-11774 induces apoptosis in colorectal cancer cells. <bold>a</bold> FACScan analysis of cells treated with IDF-11774 and 1&#x02009;nM bafilomycin A1 for 72&#x02009;h by propidium iodide (PI) staining. <bold>b</bold> Western blot analysis of cells treated with IDF-11774 and 1&#x02009;nM bafilomycin A1 for 72&#x02009;h. The signal intensity of each protein was normalized to that of GAPDH. <bold>c</bold> Scatter-grams of fluorescein isothiocyanate (FITC)-Annexin V/propidium iodide (PI) staining of WiDr and HCT116 cells treated with IDF-11774 and 1&#x02009;nM bafilomycin A1 for 72&#x02009;h. <bold>d</bold>, <bold>e</bold> Measurement of caspase-3/7 activity using the CellPlayer kinetic caspase-3/7 reagent. Caspase-3/7-positive cells appeared green under a fluorescence microscope. WiDr (<bold>d</bold>) and HCT116 cells (<bold>e</bold>) treated with IDF-11774 and 1&#x02009;nM bafilomycin A1 for 72&#x02009;h using the IncuCyte ZOOM system. Scale bar, 200&#x02009;&#x000b5;m. The concentration of IDF-11774 was 5&#x02009;&#x003bc;M in WiDr and 10&#x02009;&#x003bc;M in HCT116 cells</p></caption><graphic xlink:href="41416_2018_289_Fig4_HTML" id="d29e1118"/></fig></p></sec><sec id="Sec24"><title>Bcl-2 plays a crucial role in the synthetic lethality of IDF-11774 and ATP6V0C</title><p id="Par31">When we examined the levels of several proteins involved in PI3K signaling, Bcl-2 was found to be low in both HT29 and WiDr cells bearing the P445T mutation, and in HCT116 cells bearing the H1047R mutation in <italic>PIK3CA</italic>, but high in LoVo, colo320, and SW620, which harbor wild-type <italic>PIK3CA</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>Bcl-2 expression level is crucial for the synthetic lethality of IDF-11774 and bafilomycin A1. <bold>a</bold> Western blot analysis of Bcl-2 family protein levels in human colorectal cancer cells. The signal intensity of each protein was normalized to that of GAPDH. <bold>b</bold>&#x02013;<bold>f</bold> HCT116 cells transfected with pCMV-SPORT6- <italic>BCL2</italic> were treated with 10&#x02009;&#x000b5;M IDF-11774 and 1&#x02009;nM bafilomycin A1. <bold>b</bold> Immunofluorescence of LC3B. Scale bar, 10&#x02009;&#x000b5;m. <bold>c</bold> Autolysosome formation. Caspase-3/7 activity (<bold>d</bold>, <bold>e</bold>) and cell growth (<bold>f</bold>) were measured by IncuCyte ZOOM system. Graphs are shown as the mean&#x02009;&#x000b1;&#x02009;S.D. in different regions (n&#x02009;=&#x02009;4) of the well. <bold>g</bold> Evaluation of the change in the interaction between Bcl-2 and Bax induced by bafilomycin A1 using immunoprecipitation assay. HCT116 cells transfected with pCMV3-HA-<italic>BCL2</italic> and pCMV3-Myc-<italic>BAX</italic> were treated with 10&#x02009;&#x000b5;M IDF-11774 and 1&#x02009;nM bafilomycin A1. <bold>h</bold> Combination index of IDF-11774 with bafilomycin A1 in WiDr cells transfected with pCMV-SPORT6-<italic>BCL2</italic> and in LoVo cells transfected with si<italic>BCL2</italic>. <bold>i</bold> Model depicting Bcl-2-dependent synthetic lethal interaction of IDF-11774 and ATP6V0C</p></caption><graphic xlink:href="41416_2018_289_Fig5_HTML" id="d29e1191"/></fig></p><p id="Par32">Next, we investigated whether Bcl-2 expression affects autophagy and apoptosis during the combined treatment of HCT116 cells with IDF-11774 and bafilomycin A1. <italic>BCL2</italic> overexpression substantially reduced LC3B-II accumulation by treatment with IDF-11774 and bafilomycin A1, indicating suppression of autophagosome formation (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>). As expected, IDF-11774-induced autolysosome formation was reduced in HCT116 cells by <italic>BCL2</italic> overexpression, but increased in LoVo cells by <italic>BCL2</italic> knockdown (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref>, Supplementary Figure&#x000a0;<xref rid="MOESM3" ref-type="media">3A</xref>). Moreover, <italic>BCL2</italic> overexpression suppressed apoptosis induction by simultaneous treatment with IDF-11774 and bafilomycin A1, as shown by western blot analysis (Supplementary Figure&#x000a0;<xref rid="MOESM3" ref-type="media">3B</xref>) and caspase-3/7 activity assay (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5d, e</xref>). Notably, <italic>BCL2</italic> overexpression negated the synergistic growth-inhibitory effect of IDF-11774 and bafilomycin A1 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5f</xref>). Therefore, we examined whether bafilomycin A1 affects the interaction between Bcl-2 and Bax in the presence of IDF-11774 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5g</xref>). A co-immunoprecipitation assay demonstrated that bafilomycin A1 abolished the interaction between Bcl-2 and Bax, resulting in the induction of apoptosis. Similarly, interaction of Bcl-xL with Bax was abrogated in the presence of IDF-11774 and bafilomycin A1 (Supplementary Figure&#x000a0;<xref rid="MOESM3" ref-type="media">3C</xref>).</p><p id="Par33">To confirm the significance of the Bcl-2 level in the synthetic lethal interaction of IDF-11774, we conducted isobologram analysis and determined the changes in the CI of IDF-11774 and bafilomycin A1 in WiDr cells overexpressing <italic>BCL2</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5h</xref>, Supplementary Figure&#x000a0;<xref rid="MOESM3" ref-type="media">3D</xref>) and in <italic>BCL2</italic>-knockdown LoVo cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5h</xref>, Supplementary Figure&#x000a0;<xref rid="MOESM3" ref-type="media">3E</xref>). As expected, overexpression of <italic>BCL2</italic> in WiDr cells increased the CI from 0.85 to 1.05, while <italic>BCL2</italic> knockdown in LoVo cells reduced the CI from 1.16 to 0.98, confirming the significant effect of the Bcl-2 level on the synthetic lethality of IDF-11774 and bafilomycin A1. The correlation between Bcl-2 expression and the CIs of IDF-11774 with inhibitors of autophagosome&#x02013;lysosome fusion suggested that Bcl-2 plays a crucial role in the synthetic lethal interaction of IDF-11774 with ATP6V0C.</p><p id="Par34">On the basis of our findings, we present a model of the Bcl-2-dependent synthetic lethal interaction of IDF-11774 and ATP6V0C, as shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5i</xref>. Suppression of autolysosome formation by <italic>ATP6V0C</italic> knockdown or bafilomycin A1 induces a switch from autophagy formation to apoptosis induction, which results in the release of Bcl-2/Bcl-xL from the Bcl-2-Bax/Bak complex.</p></sec><sec id="Sec25"><title>Bcl-2-dependent growth inhibition of conditionally reprogramed cells (CRCs) by combined treatment with IDF-11774 and autophagy inhibitors</title><p id="Par35">To evaluate the potential clinical application of IDF-11774 in patients with colorectal cancer, we examined the synthetic lethality of IDF-11774 with ATP6V0C using bafilomycin A1 or chloroquine in patient-derived YL-CRCs. Western blot analysis demonstrated low levels of Bcl-2 in YL-CRC2 and YL-CRC4 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a</xref>).<fig id="Fig6"><label>Fig. 6</label><caption><p>Regulation of IDF-1174 sensitivity to conditionally reprogramed cells (CRCs) derived from patients with colon cancer. <bold>a</bold> Western blot analysis of Bcl-2 expression in the CRCs. The signal intensity of each protein was normalized to that of GAPDH. <bold>b</bold>, <bold>c</bold> Autolysosome formation in CRCs treated with 10&#x02009;&#x000b5;M IDF-11774. Scale bar, 200&#x02009;&#x000b5;m. Bars indicate the ratio of the average of LysoTracker-positive cells in different regions (<italic>n</italic>&#x02009;=&#x02009;9) of the well. <bold>d</bold>, <bold>e</bold> Growth inhibition of CRCs expressing different levels of Bcl-2 in the presence of 1&#x02009;nM bafilomycin A1 and 5&#x02009;&#x000b5;M IDF-11774 or 5&#x02009;&#x000b5;M chloroquine, as measured using IncuCyte ZOOM system. Data are presented as the single representative result of three experiments and as the mean&#x02009;&#x000b1;&#x02009;S.D. In each experiment, each treatment was repeated in triplet wells, and each well was analyzed in 4 frames. <bold>f</bold> Combination index of IDF-11774 with bafilomycin A1 (BM) or chloroquine (CQ) in CRCs</p></caption><graphic xlink:href="41416_2018_289_Fig6_HTML" id="d29e1308"/></fig></p><p id="Par36">We then investigated autolysosome formation in YL-CRCs in the presence of IDF-11774. IDF-11774-induced LysoTracker fluorescence was stronger in both YL-CRC2 and YL-CRC4 than in YL-CRC1 and YL-CRC3 (containing high levels of Bcl-2) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b, c</xref>). Combined treatment with IDF-11774 and bafilomycin A1 or chloroquine inhibited the growth of YL-CRC4, but not YL-CRC3 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6d, e</xref>). Isobologram analysis revealed a synergistic effect of IDF-11774 with bafilomycin A1 or chloroquine in YL-CRC2 and YL-CRC4, and an antagonistic effect in YL-CRC1 and YL-CRC3 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6f</xref>, Supplementary Figure&#x000a0;<xref rid="MOESM4" ref-type="media">4</xref>). These results suggested that Bcl-2 expression is a crucial biomarker for the clinical application of synthetic lethality of IDF-11774 with ATP6V0C.</p></sec></sec><sec id="Sec26" sec-type="discussion"><title>Discussion</title><p id="Par37">Stimuli such as rapamycin treatment, starvation, and an increase in the cellular AMP/ATP ratio activate AMPK to repress mTOR, which directly phosphorylates ULK1 and initiates autophagy.<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup> Autophagy plays an important role in cell survival, development, and cancer progression.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> However, autophagy can serve as a back-up mechanism when apoptosis is defective, and can lead to type II programmed cell death in collaboration with apoptosis.<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup> Many anti-cancer drugs induce autophagy, thereby conferring chemoresistance, which is relieved by V-ATPase inhibitors in cancer cells.<sup><xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref></sup> However, the mechanism of sensitization of cancer cells to anti-cancer drugs by V-ATPase inhibitors has remained unclear.<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup> Here we report that the novel HSP70 inhibitor, IDF-11774, showed a Bcl-2-dependent synthetic lethal interaction with an ATP6V0C inhibitor, resulting in synergistic apoptosis of colorectal cancer cells.</p><p id="Par38">Chemogenetic RNAi screening to identify synthetic lethal interactions is useful to establish therapeutic strategies for precision cancer medicine.<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> In our genome-wide RNAi screen, genes involved in cell cycle, proteolysis, and the lysosome were identified as candidates of synthetic lethality with IDF-11774. For further analysis, we selected <italic>ATP6V0C</italic>, which encodes a critical component of an ATP-driven proton pump V-ATPase and regulates functional autolysosome formation and the acidic tumor microenvironment.<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup> Genetic depletion of <italic>ATP6V0C</italic> disrupted lysosomal acidity and blocked autophagic flux, thereby generating non-functional autolysosomes.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> V-ATPase is upregulated in hepatocellular carcinoma<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> and knockdown of <italic>ATP6L</italic> blocked the metastasis of hepatocellular carcinoma in a xenograft model.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup></p><p id="Par39">Our study revealed that <italic>ATP6V0C</italic> knockdown blocked IDF-11774-induced functional autolysosome formation and enhanced the sensitivity of cancer cells to IDF-11774, indicating that their synthetic lethal interaction. Moreover, the synergistic effect of IDF-11774 treatment and <italic>ATP6V0C</italic> knockdown correlated with the extent of IDF-11774-mediated functional autolysosome formation in various colorectal cancer cell lines. Combined treatment with IDF-11774 and bafilomycin A1, an ATP6V0C inhibitor, resulted in synergistic apoptosis by blocking autolysosome formation in HCT116 and WiDr cells. Moreover, combination of IDF-11774 and Bafilomycin A1 gave significant inhibition of tumor growth in mouse model of HCT116 (Supplementary Figure&#x000a0;<xref rid="MOESM5" ref-type="media">5</xref>). Similarly, other inhibitors of autolysosome formation, such as chloroquine and concanamycin A, caused substantial inhibition of cancer cell growth when combined with IDF-11774. Contrastingly, proton-pump inhibitors, such as omeprazole, pantoprazole, and lansoprazole had no effect on sensitivity to IDF-11774 (Supplementary Figure&#x000a0;<xref rid="MOESM6" ref-type="media">6</xref>).</p><p id="Par40"><italic>PIK3CA</italic> mutations, which confer metastatic properties to colorectal cancer cells, are present in HCT116, WiDr, and HT29, but not in LoVo, colo320, and SW620 cells. A recent study demonstrated that cell lines bearing the H1047R mutation in PIK3CA downregulates Bcl-2, thereby promoting tumorigenesis and migration.<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> Bcl-2 suppresses not only autophagy formation by binding to Beclin 1/Atg6, but also apoptosis by blocking the pro-apoptotic activities of Bax and Bak.<sup><xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup> Our data revealed that autolysosomes were easily formed in <italic>BCL2</italic>-knockdown cells, but not in <italic>BCL2</italic>-overexpressing cells in the presence of IDF-11774. Moreover, binding of Bcl-2 to Bax was abrogated in the presence of IDF-11774 and bafilomycin A1, leading to apoptosis in cancer cells. Notably, the synthetic lethal interaction of IDF-11774 with <italic>ATP6V0C</italic> was observed in HCT116 and WiDr cells with low Bcl-2 levels, but not in LoVo or colo320 cells with high Bcl-2 levels. In contrast, the growth of CCD-18Co cells, which are normal colonocytes with relatively low levels of Bcl-2, was not affected by treatment with IDF-11774 and bafilomycin A1 (Supplementary Figure&#x000a0;<xref rid="MOESM7" ref-type="media">7</xref>). As expected, <italic>BCL2</italic> knockdown reduced the CI of simultaneous treatment of IDF-11774 and bafilomycin A1, while <italic>BCL2</italic> overexpression increased the CI. Likewise, YL-CRC2 and YL-CRC4, with low levels of Bcl-2, exhibited more autolysosome formation and stronger synergistic growth inhibition upon combined treatment with IDF-11774 and bafilomycin A1 or chloroquine compared with YL-CRC1 and YL-CRC3, which have high levels of Bcl-2. Moreover, anti-apoptotic protein Bcl-xl (<italic>BCL2L1</italic>), which was identified as a candidate for synthetic lethality with IDF-11774, showed similar effects to Bcl-2 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, Supplementary Figure&#x000a0;<xref rid="MOESM8" ref-type="media">8A</xref>). However, the pro-apoptotic Bak1 did not affect the synergistic effects of IDF-11774 and bafilomycin A1 (Supplementary Figure&#x000a0;<xref rid="MOESM8" ref-type="media">8B</xref>).</p><p id="Par41">Although our chemogenetic RNAi screening successfully identified synthetic lethal genes for IDF-11774, it has some technical limitations. We cannot exclude the possibility of false negatives because of the variability in the knockdown efficacy of more than 27,500 shRNAs of the 5043 genes included in the screening, and false positives caused by off-target silencing effects. Moreover, we might have excluded shRNAs for potential synthetic lethal genes in the screening. Recent developments in RNAi and CRISPR/Cas9 technologies and careful selection of the shRNA library might improve the identification of synthetic lethal genes in future chemogenetic RNAi screenings.</p><p id="Par42">The findings of the present study are important in the light of clinical application and directions for future research. First, we identified a synthetic lethal interaction of IDF-11774 with <italic>ATP6V0C</italic>, resulting in synergistic apoptosis of colorectal cancer cells. Second, we elucidated the mechanism of chemosensitization of cancer cells to IDF-11774 by ATP6V0C inhibitors via autolysosome formation. Finally, we identified that the Bcl-2 level is a crucial and clinically applicable biomarker for combinatorial treatment using IDF-11774 and ATP6V0C inhibitors.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec27"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41416_2018_289_MOESM1_ESM.tif"><caption><p>Supplementary Figure 1. Evaluation of candidate target genes</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41416_2018_289_MOESM2_ESM.tif"><caption><p>Supplementary Figure 2. Immunohistochemistry of ATP6V0C in colorectal cancer tissue arrays</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41416_2018_289_MOESM3_ESM.tif"><caption><p>Supplementary Figure 3. Bcl-2 expression level is crucial for the synthetic lethality of IDF-11774 and bafilomycin A1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41416_2018_289_MOESM4_ESM.tif"><caption><p>Supplementary Figure 4. Isobologram analysis</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41416_2018_289_MOESM5_ESM.tif"><caption><p>Supplementary Figure 5. In-vivo combined therapy of IDF-11774 and bafilomycin A1 in an HCT116 xenograft model</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41416_2018_289_MOESM6_ESM.tif"><caption><p>Supplementary Figure 6. Combinatorial growth inhibitory effect of IDF-11774 and proton-pump inhibitors in HCT116 cells. Combinatorial effect of IDF-11774 and bafilomycin A1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="41416_2018_289_MOESM7_ESM.tif"><caption><p>Supplementary Figure 7. Effect of a combination treatment with Bafilomycin A1 and IDF&#x02011;11774 on the growth of normal colon CCD-18Co cells</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="41416_2018_289_MOESM8_ESM.tif"><caption><p>Supplementary Figure 8. Effect of Bcl-2 family proteins on synergistic interaction of IDF-11774 and Bafilomycin A1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="41416_2018_289_MOESM9_ESM.tif"><caption><p>Supplementary Table 1. Sequences of the siRNA</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="41416_2018_289_MOESM10_ESM.tif"><caption><p>Supplementary Table 2. Sequences of the primers</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="41416_2018_289_MOESM11_ESM.tif"><caption><p>Supplementary Table 3. Data points of SRB assay in Fig. 3b</p></caption></media></supplementary-material>
</p></sec></sec></body><back><sec><title>Electronic supplementary material</title><p><bold>Supplementary information</bold> is available for this paper at 10.1038/s41416-018-0289-1.</p></sec><ack><title>Acknowledgements</title><p>This work was supported by the KRIBB Initiative program (KGM4751713), National Research Foundation (NRF) (NRF-2017R1A2B2011936 and NRF-2018R1A5A2023127) and Health Technology R&#x00026;D (HI13C2162).</p><sec id="FPar1"><title>Authors contributions</title><p id="Par43">B-K.K. designed and performed experiments and wrote part of manuscript. S.W.N. provided an initial idea and designed experiments. B.S.M. provided cancer patient-derived cell lines. HSB, J-Y.I. and J.P. performed experiment. K.L. synthesized IDF-11774. JL helped shRNA screening experiment. S-Y.K. and MK analyzed the hi-seq data of shRNA screening. H.L. and S.P. reviewed manuscript. M.W. advised all experiment and wrote a manuscript.</p></sec></ack><notes><title>Ethics approval</title><p id="Par44">All animal experimental protocols were approved by the Bioethics Committee of the Korea Research Institute of Bioscience and Biotechnology.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par45">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>AW</given-names></name><name><surname>de Silva</surname><given-names>T</given-names></name><name><surname>Bally</surname><given-names>MB</given-names></name><name><surname>Lockwood</surname><given-names>WW</given-names></name></person-group><article-title>Synthetic lethality in lung cancer and translation to clinical therapies</article-title><source>Mol. Cancer</source><year>2016</year><volume>15</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s12943-016-0546-y</pub-id><pub-id pub-id-type="pmid">27686855</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivas</surname><given-names>R</given-names></name><etal/></person-group><article-title>A network of conserved synthetic lethal interactions for exploration of precision cancer therapy</article-title><source>Mol. Cell</source><year>2016</year><volume>63</volume><fpage>514</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.06.022</pub-id><pub-id pub-id-type="pmid">27453043</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diehl</surname><given-names>P</given-names></name><name><surname>Tedesco</surname><given-names>D</given-names></name><name><surname>Chenchik</surname><given-names>A</given-names></name></person-group><article-title>Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions</article-title><source>Drug Discov. Today Technol.</source><year>2014</year><volume>11</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2013.12.002</pub-id><pub-id pub-id-type="pmid">24847648</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baratta</surname><given-names>MG</given-names></name><etal/></person-group><article-title>An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma</article-title><source>Proc. . Natl Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1073/pnas.1422165112</pub-id><pub-id pub-id-type="pmid">25535366</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schonherr</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genome-wide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis</article-title><source>Pigment. Cell. Melanoma Res.</source><year>2014</year><volume>27</volume><fpage>418</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12216</pub-id><pub-id pub-id-type="pmid">24406113</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prahallad</surname><given-names>A</given-names></name><etal/></person-group><article-title>Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</article-title><source>Nature</source><year>2012</year><volume>483</volume><fpage>100</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nature10868</pub-id><pub-id pub-id-type="pmid">22281684</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu-Sullivan</surname><given-names>N</given-names></name><etal/></person-group><article-title>Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1)</article-title><source>Oncotarget</source><year>2011</year><volume>2</volume><fpage>1254</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.406</pub-id><pub-id pub-id-type="pmid">22248814</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khorashad</surname><given-names>JS</given-names></name><etal/></person-group><article-title>shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance</article-title><source>Blood</source><year>2015</year><volume>125</volume><fpage>1772</fpage><lpage>1781</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-08-588855</pub-id><pub-id pub-id-type="pmid">25573989</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendes-Pereira</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen</article-title><source>Proc. . Natl Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>2730</fpage><lpage>2735</lpage><pub-id pub-id-type="doi">10.1073/pnas.1018872108</pub-id><pub-id pub-id-type="pmid">21482774</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>B</given-names></name><etal/></person-group><article-title>KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer</article-title><source>Cancer Res.</source><year>2013</year><volume>73</volume><fpage>5532</fpage><lpage>5543</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-0712</pub-id><pub-id pub-id-type="pmid">23824739</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>MH</given-names></name><name><surname>Nielsen</surname><given-names>H</given-names></name><name><surname>Dalton</surname><given-names>SO</given-names></name><name><surname>Johansen</surname><given-names>C</given-names></name></person-group><article-title>Cancer incidence and mortality among members of the Danish resistance movement deported to German concentration camps: 65-Year follow-up</article-title><source>Int. J. Cancer</source><year>2015</year><volume>136</volume><fpage>2476</fpage><lpage>2480</lpage><pub-id pub-id-type="doi">10.1002/ijc.29288</pub-id><pub-id pub-id-type="pmid">25346456</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Desantis</surname><given-names>C</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Colorectal cancer statistics, 2014</article-title><source>CA Cancer J. Clin.</source><year>2014</year><volume>64</volume><fpage>104</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.3322/caac.21220</pub-id><pub-id pub-id-type="pmid">24639052</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas N.</collab></person-group><article-title>Comprehensive molecular characterization of human colon and rectal cancer</article-title><source>Nature</source><year>2012</year><volume>487</volume><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nature11252</pub-id><pub-id pub-id-type="pmid">22810696</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review</article-title><source>Clin. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>2257</fpage><lpage>2268</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2410</pub-id><pub-id pub-id-type="pmid">22357840</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartwright</surname><given-names>TH</given-names></name></person-group><article-title>Treatment decisions after diagnosis of metastatic colorectal cancer</article-title><source>Clin. Colorectal Cancer</source><year>2012</year><volume>11</volume><fpage>155</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.clcc.2011.11.001</pub-id><pub-id pub-id-type="pmid">22192364</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>RM</given-names></name></person-group><article-title>Therapy for metastatic colorectal cancer</article-title><source>Oncologist</source><year>2006</year><volume>11</volume><fpage>981</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.11-9-981</pub-id><pub-id pub-id-type="pmid">17030638</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ban</surname><given-names>HS</given-names></name><etal/></person-group><article-title>The novel hypoxia-inducible factor-1alpha inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth</article-title><source>Cell Death Dis.</source><year>2017</year><volume>8</volume><fpage>e2843</fpage><pub-id pub-id-type="doi">10.1038/cddis.2017.235</pub-id><pub-id pub-id-type="pmid">28569777</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ban</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Identification of targets of the HIF-1 inhibitor IDF-11774 using alkyne-conjugated photoaffinity probes</article-title><source>Bioconjug. Chem.</source><year>2016</year><volume>27</volume><fpage>1911</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.6b00305</pub-id><pub-id pub-id-type="pmid">27386732</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BK</given-names></name><etal/></person-group><article-title>p300 cooperates with c-Jun and PARP-1 at the p300 binding site to activate RhoB transcription in NSC126188-mediated apoptosis</article-title><source>Biochim. Biophys. Acta</source><year>2014</year><volume>1839</volume><fpage>364</fpage><lpage>p373</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.03.004</pub-id><pub-id pub-id-type="pmid">24636898</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palechor-Ceron</surname><given-names>N</given-names></name><etal/></person-group><article-title>Radiation induces diffusible feeder cell factor(s) that cooperate with ROCK inhibitor to conditionally reprogram and immortalize epithelial cells</article-title><source>Am. J. Pathol.</source><year>2013</year><volume>183</volume><fpage>1862</fpage><lpage>1870</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2013.08.009</pub-id><pub-id pub-id-type="pmid">24096078</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells</article-title><source>Am. J. Pathol.</source><year>2012</year><volume>180</volume><fpage>599</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.10.036</pub-id><pub-id pub-id-type="pmid">22189618</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Im</surname><given-names>JY</given-names></name><etal/></person-group><article-title>DNA damage induced apoptosis suppressor (DDIAS) is upregulated via ERK5/MEF2B signaling and promotes beta-catenin-mediated invasion</article-title><source>Biochim. Biophys. Acta</source><year>2016</year><volume>1859</volume><fpage>1449</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2016.07.003</pub-id><pub-id pub-id-type="pmid">27412911</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>TC</given-names></name></person-group><article-title>Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies</article-title><source>Pharmacol. Rev.</source><year>2006</year><volume>58</volume><fpage>621</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1124/pr.58.3.10</pub-id><pub-id pub-id-type="pmid">16968952</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshii</surname><given-names>Saori R.</given-names></name><name><surname>Mizushima</surname><given-names>Noboru</given-names></name></person-group><article-title>Monitoring and Measuring Autophagy</article-title><source>International Journal of Molecular Sciences</source><year>2017</year><volume>18</volume><issue>9</issue><fpage>1865</fpage><pub-id pub-id-type="doi">10.3390/ijms18091865</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuboyama</surname><given-names>K</given-names></name><etal/></person-group><article-title>The ATG conjugation systems are important for degradation of the inner autophagosomal membrane</article-title><source>Science</source><year>2016</year><volume>354</volume><fpage>1036</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1126/science.aaf6136</pub-id><pub-id pub-id-type="pmid">27885029</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Im</surname><given-names>JY</given-names></name><etal/></person-group><article-title>DNA damage-induced apoptosis suppressor (DDIAS), a novel target of NFATc1, is associated with cisplatin resistance in lung cancer</article-title><source>Biochim. Biophys. Acta</source><year>2016</year><volume>1863</volume><fpage>40</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2015.10.011</pub-id><pub-id pub-id-type="pmid">26493727</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Sayans</surname><given-names>M</given-names></name><name><surname>Garcia-Garcia</surname><given-names>A</given-names></name><name><surname>Reboiras-Lopez</surname><given-names>MD</given-names></name><name><surname>Gandara-Vila</surname><given-names>P</given-names></name></person-group><article-title>Role of V-ATPases in solid tumors: importance of the subunit C (Review)</article-title><source>Int. J. Oncol.</source><year>2009</year><volume>34</volume><fpage>1513</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.3892/ijo_00000280</pub-id><pub-id pub-id-type="pmid">19424568</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangieri</surname><given-names>LR</given-names></name><etal/></person-group><article-title>ATP6V0C knockdown in neuroblastoma cells alters autophagy-lysosome pathway function and metabolism of proteins that accumulate in neurodegenerative disease</article-title><source>PLoS. ONE</source><year>2014</year><volume>9</volume><fpage>e93257</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0093257</pub-id><pub-id pub-id-type="pmid">24695574</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YT</given-names></name><etal/></person-group><article-title>Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>10850</fpage><lpage>10861</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.080796</pub-id><pub-id pub-id-type="pmid">20123989</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Noda</surname><given-names>T</given-names></name><name><surname>Yoshimori</surname><given-names>T</given-names></name></person-group><article-title>Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3</article-title><source>Autophagy</source><year>2007</year><volume>3</volume><fpage>452</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.4161/auto.4451</pub-id><pub-id pub-id-type="pmid">17534139</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragazzoni</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The thiazole derivative CPTH6 impairs autophagy</article-title><source>Cell Death Dis.</source><year>2013</year><volume>4</volume><fpage>e524</fpage><pub-id pub-id-type="doi">10.1038/cddis.2013.53</pub-id><pub-id pub-id-type="pmid">23470531</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corcelle</surname><given-names>E</given-names></name><etal/></person-group><article-title>Control of the autophagy maturation step by the MAPK ERK andp38: lessons from environmental carcinogens</article-title><source>Autophagy</source><year>2007</year><volume>3</volume><fpage>57</fpage><lpage>p39</lpage><pub-id pub-id-type="doi">10.4161/auto.3424</pub-id><pub-id pub-id-type="pmid">17102581</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marino</surname><given-names>G</given-names></name><name><surname>Niso-Santano</surname><given-names>M</given-names></name><name><surname>Baehrecke</surname><given-names>EH</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Self-consumption: the interplay of autophagy and apoptosis</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2014</year><volume>15</volume><fpage>81</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1038/nrm3735</pub-id><pub-id pub-id-type="pmid">24401948</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>EY</given-names></name><name><surname>Ryan</surname><given-names>KM</given-names></name></person-group><article-title>Autophagy and cancer--issues we need to digest</article-title><source>J. Cell. Sci.</source><year>2012</year><volume>125</volume><issue>Pt 10</issue><fpage>2349</fpage><lpage>2358</lpage><pub-id pub-id-type="doi">10.1242/jcs.093708</pub-id><pub-id pub-id-type="pmid">22641689</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decuypere</surname><given-names>JP</given-names></name><name><surname>Parys</surname><given-names>JB</given-names></name><name><surname>Bultynck</surname><given-names>G</given-names></name></person-group><article-title>Regulation of the autophagic bcl-2/beclin 1 interaction</article-title><source>Cells</source><year>2012</year><volume>1</volume><fpage>284</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.3390/cells1030284</pub-id><pub-id pub-id-type="pmid">24710477</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZJ</given-names></name><name><surname>Chee</surname><given-names>CE</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Sinicrope</surname><given-names>FA</given-names></name></person-group><article-title>The role of autophagy in cancer: therapeutic implications</article-title><source>Mol. Cancer Ther.</source><year>2011</year><volume>10</volume><fpage>1533</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0047</pub-id><pub-id pub-id-type="pmid">21878654</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvakumaran</surname><given-names>M</given-names></name><name><surname>Amaravadi</surname><given-names>RK</given-names></name><name><surname>Vasilevskaya</surname><given-names>IA</given-names></name><name><surname>O&#x02019;Dwyer</surname><given-names>PJ</given-names></name></person-group><article-title>Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy</article-title><source>Clin. Cancer Res.</source><year>2013</year><volume>19</volume><fpage>2995</fpage><lpage>3007</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1542</pub-id><pub-id pub-id-type="pmid">23461901</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>H</given-names></name><etal/></person-group><article-title>Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells</article-title><source>Cancer Chemother. Pharmacol.</source><year>2014</year><volume>74</volume><fpage>167</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/s00280-014-2451-7</pub-id><pub-id pub-id-type="pmid">24842158</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaravadi</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma</article-title><source>J. Clin. Invest.</source><year>2007</year><volume>117</volume><fpage>326</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1172/JCI28833</pub-id><pub-id pub-id-type="pmid">17235397</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fais</surname><given-names>S</given-names></name><name><surname>De Milito</surname><given-names>A</given-names></name><name><surname>You</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name></person-group><article-title>Targeting vacuolar H+-ATPases as a new strategy against cancer</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>10627</fpage><lpage>10630</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1805</pub-id><pub-id pub-id-type="pmid">18006801</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauvezin</surname><given-names>C</given-names></name><name><surname>Neufeld</surname><given-names>TP</given-names></name></person-group><article-title>Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome&#x02013;lysosome fusion</article-title><source>Autophagy</source><year>2015</year><volume>11</volume><fpage>1437</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1080/15548627.2015.1066957</pub-id><pub-id pub-id-type="pmid">26156798</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Expression and functional role of vacuolar H(+)-ATPase in human hepatocellular carcinoma</article-title><source>Carcinogenesis</source><year>2012</year><volume>33</volume><fpage>2432</fpage><lpage>2440</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgs277</pub-id><pub-id pub-id-type="pmid">22962303</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><etal/></person-group><article-title>The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>6843</fpage><lpage>6849</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3822</pub-id><pub-id pub-id-type="pmid">16061667</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>G</given-names></name><name><surname>Mahajan</surname><given-names>A</given-names></name><name><surname>Lidke</surname><given-names>D</given-names></name><name><surname>Rajput</surname><given-names>A</given-names></name></person-group><article-title>Bcl-2 together with PI3K p110alpha regulates cell morphology and cell migration</article-title><source>Cell death Dis.</source><year>2015</year><volume>6</volume><fpage>e2006</fpage><pub-id pub-id-type="doi">10.1038/cddis.2015.345</pub-id><pub-id pub-id-type="pmid">26633712</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marquez</surname><given-names>RT</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch</article-title><source>Am. J. Cancer Res.</source><year>2012</year><volume>2</volume><fpage>214</fpage><lpage>221</lpage><?supplied-pmid 22485198?><pub-id pub-id-type="pmid">22485198</pub-id></element-citation></ref></ref-list></back></article>